# OnCo record immutep (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/immutep/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "immutep" ;
  schema:name "Immutep"@en ;
  schema:alternateName "Immutep S.A.S."@en, "Immutep Limited"@en, "Prima BioMed"@en ;
  schema:description "Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer."@en ;
  schema:url <https://onco.cc/companies/immutep/>, <https://www.immutep.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Immutep> ;
  owl:sameAs <http://www.wikidata.org/entity/Q19877253> ;
  schema:citation <https://www.immutep.com>, <https://clinicaltrials.gov/search?lead=Immutep>, <https://en.wikipedia.org/wiki/Immutep> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "AU" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:targets <https://onco.cc/targets/lag3/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/nct06726265/> .